AHEL reported 13% YoY growth in standalone revenue in Q2FY18 driven by healthy growth in both healthcare services & pharmacy business. EBITDA margin declined by 163bps YoY in Q2FY18 despite healthy revenue growth primarily on account of low occupancy rate in newly added hospitals, loss in Navi Mumbai unit and impact of stent price regulation. Though consolidated EBITDA margin is expected to grow modestly in FY18E due to loss in Navi Mumbai hospital and impact of stent price regulation, however the same is expected to improve to 11.3%/12.3% in FY19E/20E....